Current Pharmaceutical Design————————个性化文献订阅—

ADAMs: Targets for Drug Discovery
[作者：Moss, ML,期刊：Current Pharmaceutical Design, 页码：2270-2271 , 文章类型： Editorial Material，,卷期：2009年15-20]

ADAM8/MS2/CD156, an Emerging Drug Target in the Treatment of Inflammatory and Invasive Pathologies
[作者：Koller, G; Schlomann, U; Golfi, P; Ferdous, T; Naus, S; Bartsch, JW,期刊：Current Pharmaceutical Design, 页码：2272-2281 , 文章类型： Review，,卷期：2009年15-20]
While it is highly accepted that ADAM family members with ubiquitous expression patterns, such as ADAM10 and ADAM17 have major roles in homoeostasis and pathology, ADAM8 was initially considered as an immune-specific ADA...

ADAM9 as a Potential Target Molecule in Cancer
[作者：Peduto, L,期刊：Current Pharmaceutical Design, 页码：2282-2287 , 文章类型： Review，,卷期：2009年15-20]
ADAM (a disintegrin and metalloproteinase) proteins have a predominant role in the protein ectodomain shedding of membrane-bound molecules. ADAMs have emerged as critical regulators of cell-cell signaling during developm...

ADAM10 as a Therapeutic Target for Cancer and Inflammation
[作者：Crawford, HC; Dempsey, PJ; Brown, G; Adam, L; Moss, ML,期刊：Current Pharmaceutical Design, 页码：2288-2299 , 文章类型： Review，,卷期：2009年15-20]
Both cancer and chronic inflammatory diseases are often marked by homeostatic signal transduction pathways run amok. Cleavage of membrane-bound substrates by extracellular metalloproteinases is frequently the rate lim...

Targeting ADAM12 in Human Disease: Head, Body or Tail?
[作者：Jacobsen, J; Wewer, UM,期刊：Current Pharmaceutical Design, 页码：2300-2310 , 文章类型： Review，,卷期：2009年15-20]
ADAM12/meltrin alpha is a type I transmembrane multidomain protein involved in tumor progression and other severe diseases, including osteoarthritis, and as such could be considered as a potential drug target. In additio...

The Therapeutic Potential of ADAM15
[作者：Lucas, N; Najy, AJ; Day, ML,期刊：Current Pharmaceutical Design, 页码：2311-2318 , 文章类型： Review，,卷期：2009年15-20]
ADAM15 is a widely expressed multi-domain protease that has been implicated in the pathogenesis of many human diseases. Given the diversity of the ADAM15 functional domains, this protease is thought to affect several imp...

ADAM17 as a Therapeutic Target in Multiple Diseases
[作者：Arribas, J; Esselens, C,期刊：Current Pharmaceutical Design, 页码：2319-2335 , 文章类型： Review，,卷期：2009年15-20]
As a metalloproteinase specialized in releasing membrane-tethered proteins, A Disintegrin and A Metalloproteinase 17 (ADAM17), also known as Tumor necrosis factor-alpha Converting Enzyme (TACE) or less commonly CD156q, h...

ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases
[作者：Qi, B; Newcomer, RG; Sang, QXA,期刊：Current Pharmaceutical Design, 页码：2336-2348 , 文章类型： Review，,卷期：2009年15-20]
A disintegrin and metalloproteinase 19 (ADAM19, or adamalysin 19) is a cell surface glycoprotein with a signal sequence, a prodomain, a metalloproteinase domain, a disintegrin domain, a cysteine-rich domain, a epiderm...

ADAM28 as a Target for Human Cancers
[作者：Mochizuki, S; Okada, Y,期刊：Current Pharmaceutical Design, 页码：2349-2358 , 文章类型： Review，,卷期：2009年15-20]
ADAM28 is a member of the ADAM (a disintegrin and metalloproteinase) gene family and consists of two isoforms, prototype membrane-type form and short secreted form. The metalloproteinase domain of ADAM28 has the zinc-bin...

A Review of the ADAMTS Family, Pharmaceutical Targets of the Future
[作者：Tortorella, MD; Malfait, F; Barve, RA; Shieh, HS; Malfait, AM,期刊：Current Pharmaceutical Design, 页码：2359-2374 , 文章类型： Review，,卷期：2009年15-20]
The a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family of metalloproteases consists of 19 members. These enzymes play an important role in the turnover of extracellular matrix proteins in vari...